NEWSROOM

123 results have been found

Corporate
Investors
Products

2019
2018
2017
2016
2015

Order by: Newest A-Z

July 31, 2019

Grifols increases its revenues by 14.3% to EUR 2,423 million, driven by its strategic growth plan

July 16, 2019

Grifols presents additional encouraging Alzheimer’s trial results at AAIC

July 4, 2019

Grifols announces FDA approval of Xembify^®, 20% subcutaneous immunoglobulin for primary immunodeficiencies

July 3, 2019

Grifols selected to build its first intravenous solutions manufacturing line in Africa

June 27, 2019

Grifols discloses transfers of value made to European healthcare professionals and health-sector organizations in 2018

Content: footer-organization-info

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.